Skip to content
Open access

Liver-eye axis in metabolic syndrome: integrated evidence from mendelian randomization, single-cell sequencing, and clinical sample validation

Sep 2026 · Frontiers in Endocrinology · Vol 17 · 0 citations · 35 references
Medicine

TL;DR

NAFLD is causally associated with an increased risk of DR development, particularly during early NPDR stages, and LTB showed the strongest effect, suggesting that LTB may play a role in the link between these two conditions.

Abstract

Background Non-alcoholic fatty liver disease (NAFLD) and diabetic retinopathy (DR) are common clinical complications of metabolic syndrome in different organ systems. However, the relationship between NAFLD and DR remains controversial, and more high-level evidence is needed to clarify the causal link between them. We aimed to investigate the causal relationship between NAFLD and DR across its progression stages, and to identify circulating proteins may mediate this association. Materials and methods Based on genetic tools, a multi-stage network MR framework was constructed, integrating NAFLD/DR genome-wide association study data and three blood proteome-wide datasets. Causal effects of NAFLD on DR were assessed using inverse-variance weighted regression and multimodal models. Proteome-wide MR identified DR-associated proteins. Bidirectional two-sample MR and mediation models quantified regulatory weights in NAFLD-protein-DR pathways. In addition, the transcriptional expression levels of the identified mediator proteins in the liver were verified through single-cell transcriptome sequencing. The levels of the mediator protein in the serum samples of clinical patients were detected by ELISA. The levels of mediator proteins in the aqueous humor and vitreous humor samples of clinical patients were detected by Luminex liquid-phase protein chip. Results NAFLD increased DR risk (OR = 1.04, 95% CI: 1.01-1.08) and specifically promoted non-proliferative DR (NPDR) progression (OR = 1.26, 95% CI: 1.05-1.52). Four proteins were identified as candidate mediators of NAFLD-DR association, among them, LTB (lymphotoxin-β, a TNF superfamily member involved in immune regulation and inflammatory responses) showed the strongest effect. In the liver of NAFLD model mice, the expression of the LTB gene was mainly elevated in T cells and B cells. The levels of LTB protein in the aqueous humor, vitreous humor and serum of NAFLD patients with DR were all higher than those of NAFLD patients without DR. Conclusions NAFLD is causally associated with an increased risk of DR development, particularly during early NPDR stages. LTB may mediate the biological process by which NAFLD promotes DR. T cells and B cells in the liver of patients with NAFLD produce higher levels of LTB protein. In NAFLD patients with DR, LTB protein levels were elevated in serum, aqueous humor, and vitreous humor compared to NAFLD patients without DR, suggesting that LTB may play a role in the link between these two conditions.

Read PDF

Similar papers

Sep 2026

Integrated bioinformatics and SEM analysis reveal GPAM as a key mediator of fibrosis in NAFLD with metabolic dysfunction

The first genetically grounded mechanism for the progression of NAFLD to fibrosis is presented, which encompasssses genetic variants, dysregulated gene expression, metabolic disturbances, and the processes involved in fibrotic remodeling.

B. Peng, Meng-Ying Xu, Li Ma et al. · 0 citations
Open access Aug 2026

Causal relationships between gut microbiota, metabolites, and chronic kidney disease: a two-step, two-sample Mendelian randomization study

Genetic evidence is provided that gut microbiota influence CKD risk partially through circulating metabolites, highlighting the gut microbiota–metabolite–CKD axis as a potential therapeutic target.

Ying Qian, Yue Yang, Zi-Yan Shen et al. · 0 citations
Open access Sep 2026

Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation

A circulating carnitine/acylcarnitine signature may serve as a non-invasive indicator of microvascular risk, and the SLC22A5–CPT2 axis represents a potential therapeutic target.

Qian Liu, Yan Liu, Xiongyi Yang et al. · 0 citations
Open access Sep 2026

Multilevel genomic, transcriptomic, and epidemiologic evidence linking diabetic retinopathy to Alzheimer disease

Genetic liability to DR is associated with an increased risk of AD and is accompanied by shared expression-mediated effects and convergent neurovascular-metabolic pathways, which support the possibility that DR may serve as a clinically accessible indicator of increased neurodegenerative vulnerability.

Jing Li, Qian Liu, Qian Ma et al. · 0 citations
Open access Oct 2026

Association of severe liver disease and diabetic retinopathy, retinal imaging phenotypes, and plasma metabolic signatures: A UK biobank study.

BACKGROUND Severe liver disease (SLD), including non-alcoholic fatty liver disease, alcoholic liver disease, viral hepatitis, and liver fibrosis/cirrhosis, is a systemic metabolic disorder that frequently coexists with diabetes. As one of the most common diabetic complications, diabetic retinopathy (DR) still has an un...

Yi Zeng, Hong-Kun Hu, Rong Rong et al. · 0 citations
Review Open access Sep 2026

Causal relationship between liver fat reduction and clinical outcomes in human genetic studies and randomized clinical trials of metabolic-dysfunction associated steatohepatitis

The largest-to-date genome-wide association study of liver fat in 79,642 people with magnetic resonance imaging and developed a polygenic score with liver fat-lowering alleles across 55 genomic loci demonstrate the profound etiologic impact of liver fat in MASH and provide compelling evidence for liver fat reductions a...

N. Verweij, G. Hindy, Q. Nguyen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.